Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neurology · Autoimmune Cerebellar Ataxia

Decoding the Antibodies: Pathology & Cancer Risk

At a Glance

In autoimmune cerebellar ataxia, the antibody type helps doctors estimate treatment response and the chance of hidden cancer. Interpretation should match symptoms and use validated tests of blood and spinal fluid; high-risk results may require repeated scans.

Antibodies are the “fingerprints” of an immune attack. In autoimmune cerebellar ataxia, finding a specific antibody can help your doctor understand why your immune system is targeting your brain and, crucially, whether there is a hidden cancer that needs to be found.

However, not all antibodies are created equal. Doctors divide them into two main categories based on where their target is located: the surface of the neuron or inside the neuron.

Surface vs. Intracellular Antibodies

This distinction is a useful starting point for predicting how well you might respond to treatment and your risk of having an underlying cancer. These are probabilistic trends, not absolute guarantees; a surface antibody can sometimes be associated with cancer, and an intracellular result can sometimes be a false positive.

Surface (Synaptic) Antibodies

These antibodies target proteins on the outside of brain cells, often interfering with how the cells “talk” to each other [1].

  • Mechanism: They often cause dysfunction rather than immediate cell death.
  • Prognosis: Because the cells are often “stunned” rather than killed, these conditions tend to be more responsive to immunotherapy (treatments that calm the immune system) [2].
  • Example: mGluR1 is a surface antibody that can cause ataxia. While it can be associated with Hodgkin lymphoma, many cases are non-cancerous and have a relatively favorable outlook [3][4].

Intracellular (Onconeural) Antibodies

These antibodies target proteins hidden inside the neurons. These are often called onconeural antibodies because they are frequently triggered by a tumor [1].

  • Mechanism: The antibodies themselves may not be the primary “killers”; instead, they are markers of a fierce attack by T-cells (immune cells that kill infected or cancerous cells), which can lead to permanent loss of neurons [5].
  • Prognosis: These conditions are often harder to treat and may lead to more significant long-term disability even after the immune system is calmed [6].

Common Antibodies and Their Meaning

Your specific antibody acts as a guide for where your doctors should look for a potential trigger.

Antibody Common Cancer Association (Paraneoplastic) Typical Characteristics
Anti-Yo (PCA-1) Breast, Ovarian, or other Gynecologic cancers [7][8]. Often causes a rapid, severe decline in balance and coordination [9].
Anti-Hu (ANNA-1) Small-cell lung cancer [10]. May involve more than just balance, including numbness or confusion [11].
Anti-Tr (DNER) Hodgkin lymphoma [12]. A strong marker for cancer; requires careful, repeated screening [13].
Anti-GAD65 Often non-paraneoplastic (not related to cancer) [14]. Associated with other autoimmune diseases like Type 1 Diabetes. Usually progresses more slowly [5].

The GAD65 Nuance

Anti-GAD65 is a common antibody that can be confusing. Many people have low levels of GAD65 antibodies (especially if they have Type 1 Diabetes) without it ever affecting their brain [15].

  • For GAD65 to be considered the cause of your ataxia, the levels usually need to be high, though the exact cutoff depends entirely on the laboratory’s specific assay [16].
  • Doctors also look for evidence that the antibody is being produced inside your spinal fluid (intrathecal synthesis) rather than just leaking in from the blood [17].

Completeness Checklist: Is Your Testing Valid?

Because these tests are complex, a single positive result is rarely enough to make a diagnosis. Ensure your testing follows these standards:

  1. Tested Both Serum and CSF: Some antibodies only show up in the blood, while others are found exclusively in the spinal fluid [18][19].
  2. Used Validated Assays: Positive screening tests should ideally be confirmed with validated assays at an experienced reference laboratory, as some tests can produce misleading false positives [20][21].
  3. Matched the “Phenotype”: The antibody found should match the symptoms you actually have. For example, if a “lung cancer antibody” is found but your symptoms are very different from the typical pattern, your doctor may treat the result with more caution [22][17].

If a high-risk antibody is found, your doctors will likely recommend intensive cancer screening (like CT or PET/CT scans) even if you feel perfectly healthy otherwise, as the neurological symptoms often appear months or even years before the tumor is large enough to be seen on standard tests [23]. 🛡️ Individuals with certain antibodies may require repeat screening based on risk-stratified guidelines (like the 2021 PNS framework), which might include scans every 4 to 6 months for several years depending on your individual profile [4].

Common questions in this guide

What is the difference between surface and intracellular antibodies in autoimmune ataxia?
Surface antibodies target proteins on the outside of neurons and often disrupt cell signaling without immediately killing the cells, so the condition may respond better to immunotherapy. Intracellular antibodies are often markers of a T-cell attack that can permanently damage neurons, making recovery more limited.
Which antibodies are most associated with cancer?
Anti-Yo is associated mainly with breast, ovarian, and other gynecologic cancers; anti-Hu is associated with small-cell lung cancer; and anti-Tr, also called DNER, is strongly associated with Hodgkin lymphoma. mGluR1 can occur with Hodgkin lymphoma but is often not linked to cancer, while anti-GAD65 is commonly non-paraneoplastic.
Does a positive autoimmune ataxia antibody test mean I have cancer?
No. A positive result does not prove that cancer is present, but some antibodies substantially increase concern for an underlying tumor. When a high-risk antibody is found, doctors may recommend CT or PET/CT imaging and repeat screening because neurological symptoms can precede tumor detection.
Why are autoimmune ataxia antibodies tested in both blood and spinal fluid?
Some antibodies are easier to detect in blood, while others may be found mainly in cerebrospinal fluid. Testing both can improve interpretation and help show whether antibodies are being produced within the nervous system rather than simply entering the spinal fluid from the blood.
What does a high anti-GAD65 level mean for cerebellar ataxia?
Low anti-GAD65 levels can occur, especially in people with type 1 diabetes, without causing brain symptoms. A neurologically meaningful result is more likely when levels are high for that laboratory's assay and there is evidence of antibody production in spinal fluid, along with symptoms that fit autoimmune ataxia.
How often might I need cancer screening after a high-risk antibody result?
The schedule depends on the antibody, symptoms, age, personal risk, and initial scan results. For some high-risk profiles, doctors may repeat CT or PET/CT scans every four to six months for several years, following an individualized risk-based plan.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Non-specific autoimmune cerebellar ataxia with characteristic antibodies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific antibody was found, and is it classified as targeting a 'surface' or an 'intracellular' protein?
  2. 2.Was the antibody test performed on both my blood (serum) and my spinal fluid (CSF), and were the results confirmed with a second, antigen-specific test?
  3. 3.Given my antibody type, what specific cancers should I be screened for, and how often will we repeat these scans?
  4. 4.For my anti-GAD65 result, is the level high enough to be considered neurologically significant, and is there evidence of 'intrathecal synthesis' (the immune system making the antibody inside the spinal fluid)?
  5. 5.How does this antibody result change my treatment plan compared to someone with no detectable antibodies?
  6. 6.Does my antibody profile suggest that my condition is more likely to respond to immunotherapy, or is it a marker of a T-cell attack that might be harder to reverse?

References

References (23)
  1. 1

    Paraneoplastic and Other Autoimmune Encephalitides: Antineuronal Antibodies, T Lymphocytes, and Questions of Pathogenesis.

    Greenlee JE, Carlson NG, Abbatemarco JR, et al.

    Frontiers in neurology 2021; (12()):744653 doi:10.3389/fneur.2021.744653.

    PMID: 35111121
  2. 2

    Advances in the Pathogenesis of Auto-antibody-Induced Cerebellar Synaptopathies.

    Mitoma H, Manto M

    Cerebellum (London, England) 2023; (22(1)):129-147 doi:10.1007/s12311-021-01359-z.

    PMID: 35064896
  3. 3

    Cerebellar long-term depression and auto-immune target of auto-antibodies: the concept of LTDpathies.

    Mitoma H, Honnorat J, Yamaguchi K, Manto M

    Molecular biomedicine 2021; (2(1)):2 doi:10.1186/s43556-020-00024-x.

    PMID: 35006439
  4. 4

    Paraneoplastic movement disorders.

    McKeon A, Tracy J

    Handbook of clinical neurology 2024; (200()):211-227 doi:10.1016/B978-0-12-823912-4.00004-9.

    PMID: 38494279
  5. 5

    Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.

    Jones AL, Flanagan EP, Pittock SJ, et al.

    JAMA neurology 2015; (72(11)):1304-12 doi:10.1001/jamaneurol.2015.2378.

    PMID: 26414229
  6. 6

    Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.

    Yshii L, Bost C, Liblau R

    Frontiers in immunology 2020; (11()):991 doi:10.3389/fimmu.2020.00991.

    PMID: 32655545
  7. 7

    A Systematic Review on Anti-Yo/PCA-1 Antibody: Beyond Cerebellar Ataxia in Middle-Aged Women with Gynecologic Cancer.

    Mendes NT, Ronchi NR, Silva GD

    Cerebellum (London, England) 2023; (22(6)):1287-1292 doi:10.1007/s12311-022-01492-3.

    PMID: 36334195
  8. 8

    Characteristics and prognosis of PCA-1 (anti-Yo) autoimmunity and the utility of the Brief Ataxia Rating Scale in a seropositive cerebellar ataxia cohort.

    Cerroni S, Hoshina Y, Glenn T, et al.

    Journal of neuroimmunology 2026; (410()):578812 doi:10.1016/j.jneuroim.2025.578812.

    PMID: 41270562
  9. 9

    Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review.

    Venkatraman A, Opal P

    Annals of clinical and translational neurology 2016; (3(8)):655-63 doi:10.1002/acn3.328.

    PMID: 27606347
  10. 10

    Autoimmune Neurology of the Central Nervous System.

    Tobin WO, Pittock SJ

    Continuum (Minneapolis, Minn.) 2017; (23(3, Neurology of Systemic Disease)):627-653 doi:10.1212/CON.0000000000000487.

    PMID: 28570322
  11. 11

    Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case report.

    Pozas J, Albarrán-Fernández V, González-Campo L, et al.

    Translational lung cancer research 2022; (11(7)):1497-1502 doi:10.21037/tlcr-21-989.

    PMID: 35958343
  12. 12

    Autoimmune Vestibulocerebellar Syndromes.

    Narayan RN, McKeon A, Fife TD

    Seminars in neurology 2020; (40(1)):97-115 doi:10.1055/s-0039-3402061.

    PMID: 31958862
  13. 13

    Cerebellar Ataxia With Anti-DNER Antibodies: Outcomes and Immunologic Features.

    Peter E, Do LD, Hannoun S, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2022; (9(5)) doi:10.1212/NXI.0000000000200018.

    PMID: 35940913
  14. 14

    GAD65 neurological autoimmunity.

    McKeon A, Tracy JA

    Muscle & nerve 2017; (56(1)):15-27 doi:10.1002/mus.25565.

    PMID: 28063151
  15. 15

    Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment.

    Muñoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2020; (7(3)) doi:10.1212/NXI.0000000000000696.

    PMID: 32123047
  16. 16

    GAD antibodies in neurological disease: a critical evaluation of the utility and treatment implications of GAD antibodies in clinical practice.

    Brown RL, Thomas-Black G, Garcia-Moreno H, et al.

    Journal of neurology 2025; (272(3)):222 doi:10.1007/s00415-025-12926-3.

    PMID: 39985693
  17. 17

    GAD antibodies in neurological disorders - insights and challenges.

    Graus F, Saiz A, Dalmau J

    Nature reviews. Neurology 2020; (16(7)):353-365 doi:10.1038/s41582-020-0359-x.

    PMID: 32457440
  18. 18

    Non-paraneoplastic Autoimmune Cerebellar Ataxia with Sensory Ataxia Associated with the Anti-Ca/ARHGAP26 Antibody: A Case Report.

    Zhang H, Duan X, Zheng W, et al.

    Cerebellum (London, England) 2026; (25(5)).

    PMID: 42814241
  19. 19

    Autoimmune Movement Disorders.

    Balint B

    Continuum (Minneapolis, Minn.) 2024; (30(4)):1088-1109 doi:10.1212/CON.0000000000001455.

    PMID: 39088289
  20. 20

    A case of Homer-3 IgG cerebellar ataxia & literature review of 15 reported cases.

    Anissian D, Dubey D, Vorasoot N, et al.

    Journal of neuroimmunology 2026; (412()):578846 doi:10.1016/j.jneuroim.2025.578846.

    PMID: 41453253
  21. 21

    Utility of Protein Microarrays for Detection of Classified and Novel Antibodies in Autoimmune Neurologic Disease.

    McKeon A, Lesnick C, Vorasoot N, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2023; (10(5)) doi:10.1212/NXI.0000000000200145.

    PMID: 37550073
  22. 22

    Immune-mediated ataxias.

    Joubert B, Rostásy K, Honnorat J

    Handbook of clinical neurology 2018; (155()):313-332 doi:10.1016/B978-0-444-64189-2.00021-4.

    PMID: 29891069
  23. 23

    Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.

    Peter E, Honnorat J, Desestret V

    Handbook of clinical neurology 2024; (200()):409-417 doi:10.1016/B978-0-12-823912-4.00014-1.

    PMID: 38494293

This page explains antibody testing and cancer risk in autoimmune cerebellar ataxia for informational purposes only and does not constitute medical advice. Your neurologist and other clinicians should interpret your results and plan any screening with you.